Infectious Bovine Rhinotracheitis (IBR / Bovine Herpesvirus-1 - BHV-1)

Infectious Bovine Rhinotracheitis (IBR) is a highly contagious, acute, and often febrile viral disease of cattle caused by Bovine Herpesvirus-1 (BHV-1), a member of the family Herpesviridae, subfamily Alphaherpesvirinae. The disease is characterized primarily by severe inflammation of the upper respiratory tract, including rhinitis, tracheitis, and conjunctivitis, but can also manifest as infectious pustular vulvovaginitis (IPV) in females, balanoposthitis in males, abortion, encephalitis in calves, and generalized systemic disease in neonates. IBR is of major economic importance worldwide, causing significant losses due to mortality, decreased milk production, weight loss, abortion storms, and trade restrictions. The virus establishes lifelong latency in the trigeminal ganglia and other sensory ganglia, with reactivation and shedding occurring during stress, immunosuppression, or corticosteroid administration. In dairy herds, IBR can lead to severe respiratory disease outbreaks, especially in young stock and feedlot cattle, while in beef herds, it is a common cause of undifferentiated bovine respiratory disease (BRD) complex. The disease is a notifiable or regulated disease in many countries, and control programs often involve vaccination, biosecurity, and test-and-cull strategies. The clinical presentation varies with the strain of the virus, route of infection, age, immune status, and presence of secondary bacterial infections. The respiratory form is most common in cattle over six months of age, while the encephalitic form is seen in calves under six months. Abortion can occur at any stage of gestation, typically between 4 and 8 months, and is often the only sign in some outbreaks. The virus is shed in nasal secretions, ocular discharge, semen, and vaginal fluids, and transmission occurs via direct contact, aerosol, fomites, and artificial insemination with contaminated semen. The incubation period is typically 2 to 6 days, and the disease runs its course in 1 to 2 weeks in uncomplicated cases. Diagnosis is based on clinical signs, virus isolation, PCR, serology (ELISA, serum neutralization), and immunohistochemistry on tissue samples. Control relies on vaccination with modified-live or inactivated vaccines, strict biosecurity, and management practices to reduce stress and prevent introduction of the virus into naive herds.

The primary causative agent is Bovine Herpesvirus-1 (BHV-1), a double-stranded DNA virus belonging to the genus Varicellovirus, subfamily Alphaherpesvirinae, family Herpesviridae. BHV-1 is further classified into subtypes: BHV-1.1 (respiratory and abortion strains), BHV-1.2a (respiratory and genital strains), and BHV-1.2b (genital strains). The virus is enveloped, with an icosahedral capsid, and is relatively labile in the environment, being inactivated by heat, lipid solvents, and common disinfectants. BHV-1 has a predilection for epithelial cells of the respiratory and genital tracts, where it causes cytolytic infection. The virus encodes several glycoproteins (gB, gC, gD, gE, gI) that are important for attachment, entry, cell-to-cell spread, and immune evasion. The gE glycoprotein is a virulence factor and is deleted in some marker vaccines (gE-negative vaccines) to allow differentiation of vaccinated from infected animals (DIVA strategy). BHV-1 can establish latency in sensory ganglia, particularly the trigeminal ganglion, and reactivation can be induced by stress, glucocorticoids, or immunosuppression. Secondary bacterial infections, particularly with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, are common complications that exacerbate the severity of respiratory disease. The virus can also be found in semen of infected bulls, leading to venereal transmission and potential contamination of frozen semen. The virus is not zoonotic, but it is closely related to other herpesviruses of ruminants, such as Bovine Herpesvirus-5 (BHV-5), which causes encephalitis in cattle.

Infectious Bovine Rhinotracheitis occurs worldwide, with a higher prevalence in intensive dairy and feedlot systems where cattle are housed in close confinement. The disease affects cattle of all ages, but clinical respiratory disease is most common in animals aged 6 months to 2 years, particularly in feedlot cattle and replacement heifers. Calves under 6 months may be protected by maternal antibodies, but they can develop the encephalitic form. The genital form (IPV) is more common in breeding herds, affecting both males and females. The virus is endemic in many countries, with seroprevalence ranging from 20% to 80% depending on region and management. Morbidity can be as high as 100% in naive herds, but mortality is usually low (1-5%) unless secondary bacterial pneumonia occurs, in which case mortality can reach 10-20%. Abortion rates in affected herds can range from 5% to 60%, depending on the stage of gestation and immune status. The disease is more severe in stressed cattle, such as those recently transported, weaned, or undergoing parturition. Seasonality is not pronounced, but outbreaks may be more common in winter when ventilation is poor. The virus is transmitted horizontally via direct contact with infected nasal, ocular, or genital secretions, and vertically via transplacental infection leading to abortion. Aerosol transmission over short distances is possible, and fomites such as contaminated equipment, feed, and water can spread the virus. Artificial insemination with contaminated semen is a significant route of transmission in dairy herds. The virus can also be spread by wildlife, such as deer and elk, which can serve as reservoirs. Economic losses arise from mortality, reduced milk production, weight loss, abortion, treatment costs, and trade restrictions. In dairy herds, a single outbreak can cause a significant drop in milk yield (up to 30%) and an increase in culling rates. The disease is a major component of the bovine respiratory disease complex (BRD), which is the most economically important disease of feedlot cattle.

BHV-1 infection begins with viral attachment to epithelial cells of the upper respiratory tract, conjunctiva, or genital mucosa via glycoprotein interactions with cellular receptors. The virus enters the cell by fusion with the plasma membrane or via endocytosis, and then replicates in the nucleus, causing cell lysis and necrosis. This leads to inflammation, edema, and exudation in the affected tissues. In the respiratory tract, the virus destroys the ciliated epithelium of the nasal passages, trachea, and bronchi, impairing mucociliary clearance and predisposing to secondary bacterial colonization. The virus also infects the conjunctiva, causing conjunctivitis and ocular discharge. The inflammatory response involves infiltration of neutrophils and macrophages, release of cytokines (IL-1, IL-6, TNF-alpha), and activation of the acute-phase response. The virus can spread to the bloodstream (viremia) and reach the placenta, causing necrosis of the cotyledons and fetal death, leading to abortion. The virus also invades sensory nerve endings and travels retrograde to the trigeminal ganglion, where it establishes latency. Reactivation occurs when the animal is stressed or immunosuppressed, leading to viral shedding and recurrence of clinical signs. In calves, the virus can spread to the central nervous system, causing nonsuppurative encephalitis with neuronal necrosis and perivascular cuffing. The systemic effects include fever, leukopenia, and depression. Secondary bacterial pneumonia, particularly with Mannheimia haemolytica, is a major complication, as the damaged respiratory epithelium allows bacterial adherence and proliferation, leading to fibrinous bronchopneumonia and sepsis. The severity of the disease is influenced by viral strain, dose, and host immune status. The virus also causes immunosuppression by downregulating MHC class I expression and inducing apoptosis of lymphocytes, which increases susceptibility to secondary infections.

Several intrinsic and extrinsic factors predispose cattle to IBR. Intrinsic factors include age (young cattle are more susceptible to respiratory disease), immune status (naive animals are at higher risk), genetic susceptibility (some breeds may be more susceptible), and stress (transport, weaning, parturition, overcrowding). Extrinsic factors include poor ventilation, high stocking density, poor hygiene, inadequate nutrition, and concurrent infections. In dairy herds, the transition period is a high-risk time due to immunosuppression and metabolic stress. In feedlots, the mixing of cattle from different sources and the stress of transport are major risk factors. Poor biosecurity, such as introduction of new animals without quarantine, increases the risk of disease introduction. Lack of vaccination or inappropriate vaccination protocols can leave herds susceptible. Environmental factors such as cold, damp, and dusty conditions can damage the respiratory mucosa and increase susceptibility. Secondary bacterial infections, particularly with Mannheimia haemolytica, are more likely in animals with viral-induced immunosuppression. Management practices that reduce stress, such as providing adequate ventilation, space, and nutrition, can reduce the incidence and severity of IBR.

The clinical signs of IBR vary depending on the form of the disease. The respiratory form is the most common and is characterized by sudden onset of high fever (104-108°F, 40-42°C), depression, anorexia, and a profuse serous nasal discharge that becomes mucopurulent within 24-48 hours. Cattle may have a painful, dry cough, and breathing may be rapid and labored. The nasal mucosa is hyperemic, with the characteristic 'red nose' appearance, and may have necrotic plaques or erosions. Conjunctivitis is common, with excessive lacrimation and photophobia. In severe cases, the trachea is involved, leading to a harsh, brassy cough. The disease can progress to bronchopneumonia, especially with secondary bacterial infection, resulting in increased respiratory effort, crackles and wheezes on auscultation, and possibly death. The genital form (IPV) is characterized by pustular lesions on the vulva and vagina in females, with a mucopurulent discharge, and balanoposthitis in males, with lesions on the penis and prepuce. These lesions are painful and may cause frequent urination and reluctance to breed. Abortion can occur at any stage of gestation, but most commonly between 4 and 8 months, and may be the only sign in some outbreaks. The aborted fetus is often autolyzed, and the placenta may be retained. The encephalitic form, seen in calves under 6 months, is characterized by neurological signs such as incoordination, circling, head pressing, convulsions, and coma, with high mortality. In neonatal calves, the virus can cause a generalized systemic disease with fever, diarrhea, and death. The severity of clinical signs is variable, and some animals may have subclinical infections. In dairy herds, a drop in milk production is often the first sign noticed by the producer.

Differential diagnoses for IBR include other causes of respiratory disease in cattle, such as Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza-3 (PI-3), Bovine Viral Diarrhea Virus (BVDV), Mannheimia haemolytica pneumonia, Pasteurella multocida pneumonia, Histophilus somni pneumonia, Mycoplasma bovis pneumonia, and infectious bovine keratoconjunctivitis (IBK). BRSV causes similar respiratory signs but is more common in young calves and often presents with acute onset of respiratory distress and fever, but without the 'red nose' and conjunctivitis. PI-3 is usually milder and often subclinical. BVDV can cause respiratory signs, but also diarrhea, immunosuppression, and reproductive disorders. Bacterial pneumonias are often secondary to viral infections and can be differentiated by culture and response to antibiotics. IBK is characterized by corneal ulcers and excessive tearing, but without nasal discharge and fever. Other differentials include bovine tuberculosis, which can cause chronic respiratory signs, and malignant catarrhal fever, which is characterized by high fever, erosive lesions, and neurological signs. Abortion due to IBR must be differentiated from other causes of abortion such as BVDV, Neospora caninum, Brucella abortus, Leptospira spp., and fungal infections. The encephalitic form must be differentiated from other causes of encephalitis such as rabies, listeriosis, and thromboembolic meningoencephalitis (TEME). Diagnosis is based on virus isolation, PCR, serology, and histopathology.

The diagnostic approach for IBR begins with a thorough herd history, including vaccination status, recent introductions, and clinical signs. Physical examination of affected animals should focus on the respiratory tract, including nasal discharge, conjunctivitis, and lung auscultation. A complete blood count may show leukopenia early in the infection. Nasal swabs, ocular swabs, or vaginal swabs should be collected for virus isolation or PCR. PCR is the most sensitive and rapid method for detecting BHV-1 DNA. Serology using ELISA or serum neutralization can detect antibodies, but paired samples (acute and convalescent) are needed to confirm a recent infection. A four-fold rise in antibody titer is diagnostic. In cases of abortion, fetal tissues (lung, liver, spleen) and placenta should be submitted for virus isolation, PCR, and immunohistochemistry. Necropsy of affected animals can reveal characteristic lesions, including necrotic rhinitis, tracheitis, and bronchopneumonia. Histopathology of the respiratory tract shows necrosis of the epithelium and intranuclear inclusion bodies. In the encephalitic form, brain tissue should be examined for nonsuppurative encephalitis. Differential diagnosis is important to rule out other respiratory pathogens. The diagnostic algorithm should also include assessment of secondary bacterial infections, which may require culture and sensitivity testing. In herds with reproductive signs, semen from bulls should be tested for BHV-1 by PCR. The use of gE-specific ELISA can differentiate vaccinated (gE-negative) from infected (gE-positive) animals, which is useful for control programs.

Laboratory findings in IBR include leukopenia, particularly lymphopenia and neutropenia, in the early stages of infection. The acute-phase response is characterized by elevated fibrinogen and haptoglobin levels. In cases with secondary bacterial pneumonia, there may be a leukocytosis with a left shift. Blood gas analysis may reveal hypoxemia and respiratory acidosis in severe respiratory disease. In cases of abortion, fetal blood or thoracic fluid may be tested for antibodies, but this is often not reliable. Virus isolation from nasal, ocular, or vaginal swabs can be performed on cell cultures, but it is time-consuming and requires specialized laboratory facilities. PCR is the preferred method for rapid detection of viral DNA. Serology using ELISA or serum neutralization can detect antibodies, but a single positive sample only indicates exposure, not active infection. Paired samples are needed to confirm a recent infection. The gE-specific ELISA is used to differentiate vaccinated from infected animals. In cases of encephalitis, cerebrospinal fluid analysis may show a lymphocytic pleocytosis and elevated protein. Histopathology of tissues reveals characteristic intranuclear inclusion bodies in epithelial cells. Immunohistochemistry can confirm the presence of viral antigen in tissues. In cases of secondary bacterial pneumonia, culture of lung tissue or transtracheal wash may reveal Mannheimia haemolytica, Pasteurella multocida, or Histophilus somni.

Imaging modalities are not commonly used for the diagnosis of IBR, but thoracic radiography and ultrasonography can be helpful in assessing the extent of pneumonia. Thoracic radiography may show cranioventral alveolar infiltrates, consistent with bronchopneumonia. Ultrasonography of the lungs can reveal consolidation, pleural effusion, and abscesses. In cases of abortion, ultrasonography of the fetus may be used to assess fetal viability, but it is not diagnostic for IBR. In cases of encephalitis, computed tomography (CT) or magnetic resonance imaging (MRI) may show lesions in the brain, but these are rarely used in cattle. Endoscopy of the upper respiratory tract can reveal the characteristic 'red nose' and necrotic plaques on the nasal mucosa and trachea. However, imaging is not a primary diagnostic tool for IBR, and the diagnosis is usually based on clinical signs and laboratory tests.

Cytology of nasal or conjunctival swabs may show necrotic epithelial cells and intranuclear inclusion bodies. Histopathology of the respiratory tract reveals necrosis of the epithelium, with infiltration of neutrophils and mononuclear cells. Intranuclear inclusion bodies (Cowdry type A) are often present in epithelial cells. In the trachea, there is severe inflammation and necrosis of the mucosa. In cases of pneumonia, there is fibrinous bronchopneumonia with areas of necrosis and hemorrhage. In the brain, histopathology shows nonsuppurative encephalitis with perivascular cuffing and neuronal necrosis. In aborted fetuses, histopathology of the liver and lung may show necrosis and intranuclear inclusion bodies. Immunohistochemistry can be used to confirm the presence of viral antigen in tissues. Cytology of bronchoalveolar lavage fluid may show neutrophils and macrophages, but it is not specific for IBR.

There is no specific antiviral treatment for IBR. Treatment is primarily supportive and aimed at controlling secondary bacterial infections and reducing fever and inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1-2.2 mg/kg IV) or meloxicam (0.5 mg/kg SC) can reduce fever and improve appetite. Antibiotics are indicated to prevent or treat secondary bacterial pneumonia. Ceftiofur (2.2 mg/kg SC q24h for 3-5 days), tulathromycin (2.5 mg/kg SC single dose), or florfenicol (40 mg/kg SC q48h for 2 doses) are commonly used. Oxytetracycline (10 mg/kg IV or IM q24h) is also effective. In severe cases, fluid therapy may be necessary to maintain hydration. Rest and good nursing care are important. In cases of abortion, no treatment is needed, but the herd should be monitored for other signs. In cases of encephalitis, treatment is usually unsuccessful, and affected calves should be euthanized. Vaccination is the most effective way to prevent IBR. Modified-live vaccines (MLV) and inactivated vaccines are available. MLV vaccines are administered intranasally or intramuscularly and provide rapid onset of immunity. Inactivated vaccines are safer for use in pregnant cows. Vaccination should be part of a comprehensive herd health program.

The prognosis for IBR is generally good in uncomplicated cases, with recovery in 1-2 weeks. However, the prognosis is guarded in cases with severe secondary bacterial pneumonia, encephalitis, or systemic disease in neonates. Mortality rates are low (1-5%) in uncomplicated outbreaks, but can be higher (10-20%) in feedlot cattle with severe pneumonia. Abortion does not affect the cow's health, but it can have a significant economic impact. The long-term prognosis for the herd is good if control measures are implemented. However, the virus establishes latency, and recovered animals can shed the virus intermittently, serving as a source of infection for naive animals. The prognosis for individual animals is good if they receive prompt treatment and supportive care. Negative prognostic indicators include severe respiratory distress, recumbency, and neurological signs.

Follow-up for IBR involves monitoring the herd for new cases and ensuring that vaccination protocols are up to date. In affected animals, monitor for resolution of clinical signs and return to normal production. In dairy herds, monitor milk production and reproductive performance. In cases of abortion, submit fetal tissues for laboratory testing to confirm the diagnosis. Implement biosecurity measures to prevent introduction of the virus into the herd. Quarantine new animals for at least 30 days and test them for BHV-1 before introduction. Vaccinate all animals according to the label recommendations. In endemic herds, consider a vaccination program using MLV vaccines for young stock and inactivated vaccines for pregnant cows. Monitor the herd for seroconversion and adjust the vaccination program as needed. In cases of secondary bacterial pneumonia, ensure that antibiotic therapy is appropriate and complete. Provide good nutrition and minimize stress to reduce the risk of reactivation of latent virus.

Clinical pearls: 1. The 'red nose' is a classic sign of IBR, but not all cases present with it. 2. Conjunctivitis with profuse lacrimation is a common early sign. 3. Abortion may be the only sign in some outbreaks, so consider IBR in any abortion storm. 4. The encephalitic form is more common in calves under 6 months and has a high mortality rate. 5. Vaccination with MLV vaccines can cause abortion if given to pregnant cows, so use inactivated vaccines in pregnant animals. 6. The gE-negative marker vaccines allow differentiation of vaccinated from infected animals, which is useful for control programs. Pitfalls: 1. Do not confuse IBR with other respiratory diseases such as BRSV or PI-3. 2. Do not rely solely on clinical signs for diagnosis; confirm with laboratory tests. 3. Do not use MLV vaccines in pregnant cows. 4. Do not ignore secondary bacterial infections, as they are a major cause of mortality. 5. Do not forget that recovered animals are latently infected and can shed the virus, so maintain strict biosecurity.

Current drug protocols for IBR focus on supportive care and control of secondary bacterial infections. NSAIDs: Flunixin meglumine (Banamine) at 1.1-2.2 mg/kg IV or IM, once daily for up to 3 days. Meloxicam (Metacam) at 0.5 mg/kg SC, single dose. Antibiotics: Ceftiofur (Excede, Naxcel) at 2.2 mg/kg SC, repeated at 72 hours for Excede, or 2.2 mg/kg SC q24h for Naxcel for 3 days. Tulathromycin (Draxxin) at 2.5 mg/kg SC, single dose. Florfenicol (Nuflor) at 40 mg/kg SC, repeated at 48 hours. Oxytetracycline (LA-200) at 10 mg/kg IM or IV, repeated at 72 hours. Enrofloxacin (Baytril) at 7.5-12.5 mg/kg SC, once daily for 3-5 days (not approved in all countries). Fluid therapy: For dehydrated animals, use isotonic fluids (LRS or 0.9% NaCl) at 20-40 mL/kg IV, as needed. For shock, use hypertonic saline (7.2%) at 4-5 mL/kg IV over 5-10 minutes, followed by oral fluids. Withdrawal times: Ceftiofur: milk 0 days, meat 3 days (Excede) or 4 days (Naxcel). Tulathromycin: milk 0 days, meat 18 days. Florfenicol: milk 0 days, meat 28 days. Oxytetracycline: milk 96 hours, meat 28 days. Enrofloxacin: milk 0 days, meat 7 days (check local regulations). Always follow label directions and consult with a veterinarian.

Landmark studies on IBR have established the efficacy of vaccination in reducing clinical disease and viral shedding. A meta-analysis by Fulton et al. (2000) showed that MLV vaccines significantly reduced the incidence of BRD in feedlot cattle. Studies by van Drunen Littel-van den Hurk et al. (2001) demonstrated that gE-deleted marker vaccines provide effective immunity and allow DIVA strategies. Research on the pathogenesis of BHV-1 has shown that the virus induces immunosuppression by downregulating MHC class I expression (Hinkley et al., 1998). The economic impact of IBR was quantified by Hage et al. (2003), who found that a single outbreak in a dairy herd resulted in a 30% reduction in milk yield and increased culling. Consensus guidelines from the AABP and ECBHM recommend vaccination as the cornerstone of IBR control, along with biosecurity and test-and-cull programs. Recent studies have focused on the development of novel vaccines, including subunit and vectored vaccines, which show promise in providing broader protection and differentiating infected from vaccinated animals. Overall, the evidence supports the use of vaccination to reduce the impact of IBR, but emphasizes the importance of comprehensive herd health management.